Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC - Episode 2

Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

,

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

EP. 1: How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC
Now Viewing
EP. 2: Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T
EP. 3: Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC
EP. 4: Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC
EP. 5: Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC
EP. 6: How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management
EP. 7: Unmet Needs Research Aims to Address in Early-Stage NSCLC

Related Content:

Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLCOncLive News Network®Lung CancerImmuno-Oncology
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence
VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors